正确剂量,即刻给予:重症患者的个体化药物给药
本文为综述,讨论重症患者抗生素个体化给药的必要性与实施路径。作者认为给予正确剂量可能提高感染临床治愈率、抑制耐药病原体出现,在病情严重度较高的患者中个体化给药还可能降低死亡率。实现优化给药应将基于证据的给药列线图或给药软件联合治疗药物监测数据嵌入日常实践,并尽早启动治疗,因缩短启动时间已显示可改善患者生存,尤其在脓毒症休克时。但支持这些逻辑路径的稳健数据缺乏,需要大型前瞻性研究评估患者生存与卫生系统成本。
要点
- 作者认为给予正确剂量很可能提高感染临床治愈概率并抑制耐药病原体出现。
- 在病情严重度较高的患者中,优化抗生素使用还可能降低死亡率。
- 个体化给药方案应通过基于证据的给药列线图或给药软件联合治疗药物监测数据嵌入日常实践。
- 个体化给药方案应尽可能早给予,因缩短启动治疗时间已显示改善患者生存,尤其在脓毒症休克时。
- 支持个体化抗生素给药的稳健数据缺乏,需要大型前瞻性研究评估患者生存与卫生系统成本。
适用人群与场景
- 重症患者,尤其是感染的重症患者。
- 病情严重度较高的患者。
- 脓毒症休克患者。
处置流程与药物剂量
- 作者认为应通过基于证据的给药列线图实现个体化给药方案。
- 作者认为应优先通过给药软件联合治疗药物监测数据实现个体化给药方案。
- 个体化给药方案应嵌入日常实践。
- 个体化给药方案应尽可能早给予。
研究设计与关键结果
- 本文为综述,讨论重症患者抗生素个体化给药的必要性、实施路径与证据缺口。
- 作者指出支持个体化抗生素给药的稳健数据缺乏,需要大型前瞻性研究评估患者生存与卫生系统成本。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为应将基于证据的给药列线图或给药软件联合治疗药物监测数据嵌入日常实践,以给予正确剂量。
- 作者认为个体化给药方案应尽可能早给予,尤其在脓毒症休克患者中。
- 作者指出支持上述路径的稳健数据缺乏,需要大型前瞻性研究评估患者生存与卫生系统成本。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Drugs are key weapons that clinicians have to battle against the profound pathologies encountered in critically ill patients. Antibiotics in particular are commonly used and can improve patient outcomes dramatically. Despite this, there are strong opportunities for further reducing the persisting poor outcomes for infected critically ill patients. However, taking these next steps for improving patient care requires a new approach to antibiotic therapy. Giving the right dose is highly likely to increase the probability of clinical cure from infection and suppress the emergence of resistant pathogens. Furthermore, in some patients with higher levels of sickness severity, reduced mortality from an optimized approach to antibiotic use could also occur. To enable optimized dosing, the use of customized dosing regimens through either evidence-based dosing nomograms or preferably through the use of dosing software supplemented by therapeutic drug monitoring data should be embedded into daily practice. These customized dosing regimens should also be given as soon as practicable as reduced time to initiation of therapy has been shown to improve patient survival, particularly in the presence of septic shock. However, robust data supporting these logical approaches to therapy, which may deliver the next step change improvement for treatment of infections in critically ill patients, are lacking. Large prospective studies of patient survival and health system costs are now required to determine the value of customized antibiotic dosing, that is, giving the right dose at the right time.
参考来源
- Roberts JA, Kumar A, Lipman J, et al. Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. Crit Care Med. 2017. PMID: 28098629. doi:10.1097/CCM.0000000000002210
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。